<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE ipharmsciencia.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item,item,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>Internationale-Pharmaceutica-Sciencia-ISSUE VOLUME Volume 10 ISSUE Issue 1</title>
<link>http://ipharmsciencia.edwiserinternational.com/rss-feed.php</link>
<description>
Internationale-Pharmaceutica-Sciencia: VOLUME Volume 10 ISSUE Issue 1,  2020
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>Internationale-Pharmaceutica-Sciencia-ISSUE VOLUME Volume 10 ISSUE Issue 1</title>
<link>http://ipharmsciencia.edwiserinternational.com/rss-feed.php</link>
<url>http://ipharmsciencia.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>General-Overview-on-Anti-epileptic-Screening-Models-for-Plant-MoleculesSynthesized-Molecules</title>
		<pubDate>14-Aug-2020</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/3Y0UR6.pdf</link>
		<author>Neha-Tyagi-Santosh-K-Verma-and-Ajeet</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[This paper reviews model advances in epilepsy in recent years. Epilepsy is the commonest serious neurological condition, with a prevalence of 0.51% and Epilepsy is a chronic neurological condition characterized by recurrent seizures. Use of appropriate animal models is essential because epileptogenesis and seizure generation in temporal lobe epilepsy and other forms of epilepsy cannot be fully acquired in clinical studies with humans. Seizures are a combination of electrical and behavioral events that can induce chemical, molecular, and anatomic alterations.  In this review, we summarize the most frequently used models of chronic epilepsy and models of acute seizures induced by electrical and chemical kindling. Kindling is animal models of epilepsy induced by electrical stimulation of the brain. Seizures are induced with minimal neuronal damage, which could greatly enhance our ability to define the basis for the initiation and remission of spontaneous seizure. Various animal models are also critical for elucidating the mechanisms underlying neurologic dysfunctions induced by developmental alcohol exposure and for uncovering the evolutionarily conserved mechanisms of epileptogenesis.]]>}</description>
		</item><item>
		<title>Plant-Therapy-of-Corona-Virus-</title>
		<pubDate>14-Aug-2020</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/8h4wFG.pdf</link>
		<author>Vikrant-Verma</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[COVID-19 caused by SARS-CoV-2 is declared global pandemic. The virus owing high resemblance with SARS-CoV and MERS-CoV has been placed in family of beta-coronavirus. Effective management strategy with potential drug availability will break the virus transmission chain subsequently reduce the pressure on the healthcare system. Extensive research trials are underway to develop novel efficient therapeutics against SARS-CoV-2. In this review, medicinal plants are discussed which could serve as potential candidates for drug development against COVID19 infection.]]>}</description>
		</item><item>
		<title>Formulation-and-Evaluation-of-Cubosomal-Gel-of-an-Anti-Inflammatory-Agent</title>
		<pubDate>14-Aug-2020</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/9N0atD.pdf</link>
		<author>Anand-B-Thomas-I-Abraham-E</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[The present research has been undertaken with the aim to develop a transdermal Cubosomal gel formulation of Ketoprofen, which would attenuate the gastrointestinal toxicities associated with oral administration. This research also aimed to encapsulate high drug pay load in Cubosomes for improved therapeutic efficiency. Cubosomes were prepared by Top- down technique.  Different formulations (F1  F9) were prepared and optimized for better performance in terms of drug content, SEM analysis, Zeta potential, entrapment efficiency and drug release. From F F9 formulations, studies showed that F7 is better. Then it is formulated into gel using carbopol as gel base. The physical parameters like appearance, pH, viscosity, spredability, extrudability, ex- vivo drug release and in vitro skin irritation test using HET- CAM, were also evaluated. The cubosomal gel formulation (F7) was found to be clear without any aggregate indicating excellent homogenicity. The pH of the formulation was found close to neutral, indicating the absence of skin irritation. In vitro skin irritation study also reveals there is no skin irritation. The ex-vivo drug release study shows that the formulation (F7) has a good release rate when compared to other topical gels (87.2%). The kinetic study of the optimized formulation (F7) was also carried out and found that the formulation undergoes zero order kinetics.  The mechanism of drug release was found to be Higuchi model.  ]]>}</description>
		</item><item>
		<title>An-Overview-of-Clinical-Pharmacology-of-Delafloxacin</title>
		<pubDate>14-Aug-2020</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/OBnMWg.pdf</link>
		<author>Rehman-H-and-Naveed-S</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Objective: Delafloxacin is fluoroquinolone antibiotics indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI). It is new addition in the class of fluoroquinolone and shows better results with the pathogen Streptococcus pyogenes, Streptococcus agalactiae, Staphylococcus aureus and Methicillin with both susceptible and resistant conditions. By viewing, the current paper is based on clinical pharmacology and practice of Delafloxacin. Methods: Phase I, II and III clinical trial has published on clinical efficacy and safety. Till phase III clinical trial, there is no significance safety concerns appeared. The article concludes the clinical pharmacology of Delafloxacin include basic mechanism of action, clinical pharmacology including pharmacokinetics and dynamics, clinical Efficacy and indicated the current therapeutic uses and practices. Key Findings: No significant drug interaction has been reported yet and showed good tolerance in phase III clinical trial. Conclusion: Delafloxacin can considered to be the best attractive option for gram positive and expect more usage with new practices and indications in future. ]]>}</description>
		</item><item>
		<title>Microemulsions-A-Review</title>
		<pubDate>14-Aug-2020</pubDate>
<link>http://ipharmsciencia.edwiserinternational.com/admin/uploads/jryFDU.pdf</link>
		<author>Sujatha-B-Himabindu-E-Battu-S-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Microemulsions are have appear as novel vehicles for drug delivery system, microemulsions clear, stable, isotropic mixtures of oil, water and surfactants, frequently in combination with co-surfactants. Microemulsions acts as potential drug carrier systems for oral, topical, and parenteral administration. They are having the advantages like spontaneous formation, thermodynamically stable, ease of manufacturing and scale-up, improved drug solubilization and bioavailability, long self-life]]>}</description>
		</item></channel>